tDCS and Cognitive Training for Alzheimer Disease

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Alzheimer Disease
tDCS and Cognitive Training - Other
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial will test whether administering transcranial direct current stimulation (tDCS) at 4.0 mA, rather than the conventional 2mA, will produce more significant improvements in people with Alzheimer's Disease.

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 0 Secondary · Reporting Duration: 3 months

3 months
N-Back

Trial Safety

Trial Design

3 Treatment Groups

2mA Stimulation
1 of 3
4mA Stimulation
1 of 3
SHAM
1 of 3
Active Control
Experimental Treatment
Non-Treatment Group

42 Total Participants · 3 Treatment Groups

Primary Treatment: tDCS and Cognitive Training · Has Placebo Group · N/A

4mA Stimulation
Other
Experimental Group · 1 Intervention: tDCS and Cognitive Training · Intervention Types: Other
2mA Stimulation
Other
ActiveComparator Group · 1 Intervention: tDCS and Cognitive Training · Intervention Types: Other
SHAM
Other
ShamComparator Group · 1 Intervention: tDCS and Cognitive Training · Intervention Types: Other

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 3 months

Who is running the clinical trial?

BrightFocus FoundationOTHER
3 Previous Clinical Trials
246 Total Patients Enrolled
2 Trials studying Alzheimer Disease
190 Patients Enrolled for Alzheimer Disease
BaycrestLead Sponsor
40 Previous Clinical Trials
5,663 Total Patients Enrolled
4 Trials studying Alzheimer Disease
411 Patients Enrolled for Alzheimer Disease

Eligibility Criteria

Age 18+ · All Participants · 3 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 7th, 2021

Last Reviewed: October 4th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.